These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36882724)

  • 1. A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia.
    Scutari R; Fox V; De Ioris MA; Fini V; Granaglia A; Costabile V; Colagrossi L; Russo C; Mastronuzzi A; Locatelli F; Perno CF; Alteri C
    BMC Infect Dis; 2023 Mar; 23(1):133. PubMed ID: 36882724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.
    Sharma D; Notarte KI; Fernandez RA; Lippi G; Gromiha MM; Henry BM
    J Med Virol; 2023 Jan; 95(1):e28241. PubMed ID: 36263448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G
    Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart.
    Girardi V; Gularte JS; Demoliner M; da Silva MS; Filippi M; de Abreu Góes Pereira VM; Hansen AW; Rosa RB; Fleck JD; Spilki FR
    Braz J Microbiol; 2023 Sep; 54(3):1847-1851. PubMed ID: 37269428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of rapid antigen tests (RAT) for COVID-19 and factors associated with RAT-negative results among RT-PCR-positive individuals during Omicron BA.2, BA.5 and XBB.1 predominance.
    Tan CY; Zeng K; Cui L; Lin RTP; Chen M
    BMC Infect Dis; 2024 May; 24(1):504. PubMed ID: 38769524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection.
    Mencacci A; Gili A; Camilloni B; Bicchieraro G; Spaccapelo R; Bietta C; Stracci F
    J Infect Public Health; 2022 Sep; 15(9):983-985. PubMed ID: 35963101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma.
    Hashmi SK; Bodea J; Patni T; Angel S; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Wolf J; Li Y; Pui CH; Hijano DR; Inaba H
    JAMA Netw Open; 2024 Feb; 7(2):e2355727. PubMed ID: 38363571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
    Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
    Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.
    Oltolini C; Acerbis A; Orofino G; Racca S; Noviello M; Dispinseri S; Clementi N; Piemontese S; Xue E; Giglio F; Lupo Stanghellini MT; Diral E; Bruno A; Tassi E; Beretta V; Marzinotto I; Scarlatti G; Lampasona V; Ardemagni A; Sampaolo M; Bonini C; Corti C; Peccatori J; Castagna A; Ciceri F; Greco R
    Front Immunol; 2023; 14():1184956. PubMed ID: 37287986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).
    Ciuffreda L; Lorenzo-Salazar JM; García-Martínez de Artola D; Gil-Campesino H; Alcoba-Florez J; Rodríguez-Pérez H; Íñigo-Campos A; Salas-Hernández J; Rodríguez-Nuñez J; Muñoz-Barrera A; Valenzuela-Fernández A; Díez-Gil O; González-Montelongo R; Flores C
    Emerg Microbes Infect; 2023 Dec; 12(1):2202281. PubMed ID: 37039029
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
    Arora P; Zhang L; Krüger N; Rocha C; Sidarovich A; Schulz S; Kempf A; Graichen L; Moldenhauer AS; Cossmann A; Dopfer-Jablonka A; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
    Cell Host Microbe; 2022 Aug; 30(8):1103-1111.e6. PubMed ID: 35588741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.